Gil Yosipovitch, MD
Gil Yosipovitch, MD is a tenured Professor and Stiefel endowed Chair of Medical Dermatology at the Dr Phillip Frost Department of Dermatology at the Miller School of Medicine at University of Miami. He is the Director of the Miami Itch Clinical and Research Center and the UCare center for treatment of urticaria. Prior to joining the faculty of University of Miami, Dr. Yosipovitch was Founding Chair the Department of Dermatology at Temple University and directed the first translational, clinical and research center dedicated to the study of chronic itch in the US. He has published more than 700 articles in books and peer reviewed journals and has edited 6 books with total citations in google scholar of more than 39000 and H index of 101. Dr. Yosipovitch has given more than 500 invited lectures to dermatology groups and organizations around the world and has mentored more than 40 fellows, PhD students and post-Doc fellows. He is the founder and past President of the International Forum for the Study of Itch and member of its board. He served as Chairman of the Scientific Board of the National Eczema Association and member of the Scientific Board of The National Psoriasis Foundation and IEC. He serves on the editorial boards of 9 key specialty journals and is Associate editor of Journal of Investigative Dermatology and JEADV. In addition, he received one of the highest awards in dermatology, the Marion B. Sulzberger lectureship award, at the 2016 AAD meeting for his work on itch. Dr. Yosipovitch has given more than 500 invited lectures to dermatology groups and organizations around the world and has mentored more than 40 fellows, PhD students and post-Doc fellows.
Financial relationships
-
Attribution:SelfType of financial relationship:AdvisorIneligible company:RegeneronTopic:ItchDate added:07/06/2026Date updated:07/06/2026
-
Attribution:SelfType of financial relationship:AdvisorIneligible company:SanofiTopic:itchDate added:07/06/2026Date updated:07/06/2026
-
Attribution:SelfType of financial relationship:AdvisorIneligible company:GaldermaTopic:itchDate added:07/06/2026Date updated:07/06/2026
-
Attribution:SelfType of financial relationship:AdvisorIneligible company:NovartisTopic:ItchDate added:07/06/2026Date updated:07/06/2026
-
Attribution:SelfType of financial relationship:Independent contractor (including contracted research)Ineligible company:SanofiTopic:Itch, ECZEMADate added:07/06/2026Date updated:07/06/2026
-
Attribution:SelfType of financial relationship:Independent contractor (including contracted research)Ineligible company:REGENERON, SANOFITopic:EczemaDate added:07/06/2026Date updated:07/06/2026
-
Attribution:SelfType of financial relationship:AdvisorIneligible company:CelldexTopic:ItchDate added:07/06/2026Date updated:07/06/2026
-
Attribution:SelfType of financial relationship:AdvisorIneligible company:LEOTopic:ItchDate added:07/06/2026Date updated:07/06/2026
-
Attribution:SelfType of financial relationship:AdvisorIneligible company:Eli LillyTopic:ItchDate added:07/06/2026Date updated:07/06/2026
-
Attribution:SelfType of financial relationship:AdvisorIneligible company:IncyteTopic:ItchDate added:07/06/2026Date updated:07/06/2026

Facebook
X
LinkedIn
Forward